Background:Colorectal cancer (CRC) is a common malignant tumor of the gastrointestinal tract, constituting 10% of new colorectal cancer cases each year. Despite major breakthroughs in the treatment of colorectal cancer, 40-50% of patients are likely to develop local or distant tumor recurrences, and survival rates are poor. Aim of the workis to evaluate the levels of annexin A3 and thymidine phosphorylase in patients with colorectal cancer and compare these levels with control persons and to ascertain whether annexin A3 and thymidine phosphorylase are involved in the progression of the colorectal cancer and their impact on patient outcome. Patients and methods: This study was performed at Sohag University Hospital from December 2015 to December 2016 , Seventy five patients were enrolled in the study and divided into two groups. 60 patients with colorectal cancer, 15 patients with benign colorectal disease. All were matched for age and sex, for each participant body mass index (BMI), blood pressure, Annexin A3 by Eliza kit , Thymidine phosphorylase by colorimetric method were performed. Results:There were significant relations between Annexin A3and Thymidine phosphorylase and age.Significant relations were observed between Annexin A3and Thymidine phosphorylase and type of cancer.Strong positive correlation was observed between Annexin A3and Thymidine phosphorylase. Conculsion :we conclude that both of Annexin A3 and Thymidine phosphorylase were positive correlated with type and grade of colorectal cancer .So using Annexin A3 and thymidine phosphorylase as positive biomarker in the progression of colorectal cancer may be beneficial.
Introduction
Colorectal cancer (CRC) is the third most common cancer worldwide,(1) .Most CRC arises from precursor adenomatous polyps(2). stage at detection is critically related to patient survival.localized cancers (Tumournode-metastasis[TNM]Stages1-2) have an excellent 5-yearsurvival prognosis (93%and98%); regional stage (TNM Stage3) patients have a 5-year survival rate about 60%; only 8% of patients with the late stage (TNM Stage4) disease will survive 5 years(3) . Ca 2+ -dependent phospholipid-binding proteins, Annexins, are involved in cellular processes, including apoptosis, proliferation and differentiation (٤).Overexpression of Annexin A1 has been found in numerous cancer types (٥). Annexin A2 induces angiogenesis by regulating the extracellular matrix metalloproteinase inducer. Furthermore, overexpression of Annexin A2 has been associated with the development, invasion and distant metastases of various tumors (٦). Compared with other Annexins, few previous studies have investigated the function of Annexin A3. Annexin A3 staining was markedly decreased or absent in prostate cancer and was found to correlate inversely with primary tumour stage and Gleason grade (٧). Yan et al, (٨)previously showed that the increased expression of Annexin A3 is a mechanism of platinum resistance in ovarian cancer. Similarly, the Annexin A3 gene is silenced by micro RNA(miRNA) which is asmall noncoding RNAmolecule(containing about 22 nucleotides)and functions via basepairing with complementary sequences with mRNA molecules. These mRNAmolecules are silenced by one or more of the following processes:1)cleavage of the mRNA strand into two pieces,2)destabilization of its poly (A)tail,and3) less efficient translation of the mRNA into proteins by ribosomes ( ٩ ), induced apoptosis and inhibits the growth of human gallbladder cancer cells (١٠), these contradictory studies led the present study to investigate the roles of Annexin A3 expression in colorectal cancer. Thymidine phosphorylase (TP) catalyses the conversion of thymidine and 2-deoxyuridine to their respective bases and 2-α-deoxyribose-1-phosphate ( ١١). TP is also involved in endothelial cell chemotaxis in vitro and angiogenesis in vivo (1٢). TP expression in various kinds of tumors is higher than in the adjacent non neoplastic tissues, and numerous studies have consistently reported that the level of TP expression in cancer cells is closely associated with malignancy and or angiogenesis ( ١٣).
However, incolorectal carcinomas, TP expression is an independent indicator of un favorable prognosis irrespective of angiogenetic activity (1٤) To date, 5-fluorouracil (5-FU) constitutes the fundamental basis of chemotherapy treatment for patients with colorectal cancer. The enzyme thymidine phosphorylase (TP; E.C. 2.4.2.4) catalyzes the conversion of 5-FU to its more active nucleoside form, 5-fluoro-2'-deoxyuridine, representing one of the main pathways by which this drug exerts its cytotoxic effect (١١) .
In the cell, TP is involved in pyrimidine metabolism. Previous studies have shown that TP levels are higher in tumour compared with normal tissues in a wide range of solid tumours ( 1٥)TP and its catalytic product, 2-deoxy-Dribose-1-phosphate act as angiogenic factors via induction of endothelial cell migration and tube formation (1٦).In hypoxic environments, TP may also impart resistance to apoptosis (١١). TP expression is observed in tumour epithelial cells and stromal cells, particularly in tumour-associated macrophages (TAMs) (1٧).
Patients and methods
This study was performed at Sohag University Hospital from December 2015 to December 2016 , Seventy five patients were enrolled in the study and divided into two groups. 60 patients with colorectal cancer, 15 patients with benign colorectal disease. All were matched for age and sex, for each participant body mass index (BMI), blood pressure, Annexin A3 , Thymidine phosphorylase , were performed . After approval of Ethical committee of Sohag faculty of Medicine informed written consents were obtained from all individuals included in the study. All individuals were informed regarding the tests and their clinical meanings before the study.The control group included 15 persons from outpatient clinic.
Ethical Consideration:
After approval of Ethical committee of SohagFaculty of Medicine informed written consents will be obtained from all subjects included in the study.
Method:
Blood samples will be withdrawn from patients and control persons, and then centrifuged in centrifuge system for 10 minutes. Serum will be removed then the samples will be stored in aliquot at -20 ºC until assay. 2.9 ± 0.9 2.7 (1.9 -4.2) 2.9 ± 0.9 2.7 (1.8 -4.2) 0.140 10.02 ± 2.04 9.8 (5.5 -13)
10.3 ± 2.4 9.9 (7.6 -15.1) 12.5 ± 2.01 13 (7.7 -15)
4.2 ± 0.8 4.1 (2.6 -5.5) 3.9 ± 1.6 4.6 (1.2 -5.6) 4.9 ± 0.5 4.9 (3.6 -5. (39/60) of colorectal cancer specimens showed Annexin A3 immunoreactivity . Annexin A3 was predominantly expressed in the cytoplasm of cancer cells. To improve the investigation of the role of Annexin A3 in colorectal cancer, the correlation between Annexin A3 expression and clinicopathological factors was analyzed. Tumor size and Dukes' stage exhibited statistically significant correlations with Annexin A3 expression . However, no significant correlation was identified between the levels of Annexin A3 expression and other clinical and pathological features, including gender, age, tumor localization, tumor differentiation degree and lymph node metastasis(2٢). The association of thymidine phosphorylase with colorectal cancer: Thymidine phosphorylase (TP) is wellknown to be identical with plateletderived endothelial cell growth factor (PD-ECGF) as an angiogenic factor. In addition, TP is also known to be an essential enzyme for the activation of capecitabine, a new oral fluoropyrimidine, which is now being globally prescribed for colorectal and breast cancer patients as a standard chemotherapy regimen (2٣).
Thymidine phosphorylase in serum:
From 88 patients with colorectal cancer, specimens of venous blood drainage were obtained during operation. The serum TP levels were measured by ahighly sensitive Enzyme Linked Immunosorbent Assay(ELIZA)method. Subsequently,88 patients were divided into two groups based on the levels ofTP. The dividing line was determined to be55ng/ml.The TP-high group (greater than;55ng/ml)had asignificantly shorter overall survival than the TPlowgroup(lower than;55ng/ml). Amultivariate analysis indicated that the serumTP level in venous blood drainage specimens to be abetter prognostic factor independent of the traditional pathologic parameters (2٤). This agreed with our result which showed significant difference between TP in the three studied groups (mean in malignant group 147.64±13.33 ,in benign group 70.85±4.59,in healthy control 29.09±5.73)(p value <0.001). This reported that TP and its catalytic product, 2-deoxy-D-ribose-1-phosphate act as angiogenicfactors via induction of endothelial cell migration and tube formation (2٥). In hypoxic environments,TP may also impart resistance to apoptosis (11,2٦). TP expression is observed in tumour epithelial cells and stromal cells, particularly in tumour-associated macrophages(TAMs) (16,17,2٧ 
